97. Competition Experiments for the Baloxavir-Resistant I38T Influenza A Mutant

BACKGROUND: Baloxavir marboxil (BXM), a cap-dependent endonuclease inhibitor, has been recently approved in the United States for the treatment of influenza infections. It is superior to oseltamivir for reducing the time of viral shedding but is reported to have a low barrier of resistance. We sough...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Open Forum Infect Dis
Huvudupphovsmän: Checkmahomed, Liva, Mhamdi, Zeineb, Carbonneau, Julie, Baz, Mariana, Abed, Yacine, Boivin, Guy
Materialtyp: Artigo
Språk:Inglês
Publicerad: Oxford University Press 2019
Ämnen:
Abstracts
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6808909/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz359.021
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk